Treatment Information & Off-Label Disclaimer
FDA “Off-Label” Use Disclaimer: Ketamine is approved by the U.S. Food and Drug Administration (FDA) as a sole anesthetic agent for diagnostic and surgical procedures. However, the use of intravenous (IV) Ketamine for the treatment of psychiatric disorders—including Major Depressive Disorder, Generalized Anxiety Disorder, PTSD, and bipolar depression—is considered “off-label.” This means that while extensive clinical research and real-world evidence support its efficacy for these conditions, the FDA has not formally approved IV Ketamine specifically for mental health treatments.
No Guarantee of Results: While many patients experience significant relief from their symptoms following Ketamine infusion therapy, individual results vary. Betterclinix does not guarantee a cure or specific outcome for any medical or psychiatric condition. Ketamine therapy is most effective when used as part of a comprehensive treatment plan that includes ongoing psychiatric care and psychotherapy.
Potential Risks & Side Effects: Ketamine is generally well-tolerated in the clinical setting, but side effects can occur. These may include, but are not limited to:
- Mild to moderate dissociation (a feeling of detachment from reality).
- Transient increases in blood pressure and heart rate.
- Nausea or vomiting.
- Dizziness, blurred vision, or grogginess. Our clinical team utilizes continuous cardiac and vital sign monitoring to manage and mitigate these risks during your infusion.






